Neurochemical Research

, Volume 30, Issue 5, pp 677–683

Topiramate does not Alter the Kinetics of Arachidonic or Docosahexaenoic Acid in Brain Phospholipids of the Unanesthetized Rat

Authors

  • Ho-Joo Lee
    • Brain Physiology and Metabolism SectionNational Institute on Aging, National Institutes of Health
  • Sandra Ghelardoni
    • Brain Physiology and Metabolism SectionNational Institute on Aging, National Institutes of Health
  • Lisa Chang
    • Brain Physiology and Metabolism SectionNational Institute on Aging, National Institutes of Health
  • Francesca Bosetti
    • Brain Physiology and Metabolism SectionNational Institute on Aging, National Institutes of Health
  • Stanley I. Rapoport
    • Brain Physiology and Metabolism SectionNational Institute on Aging, National Institutes of Health
    • Brain Physiology and Metabolism SectionNational Institute on Aging, National Institutes of Health
Article

DOI: 10.1007/s11064-005-2756-3

Cite this article as:
Lee, H., Ghelardoni, S., Chang, L. et al. Neurochem Res (2005) 30: 677. doi:10.1007/s11064-005-2756-3

Abstract

Interest in the potential therapeutic utility of topiramate for treating bipolar disorder was stimulated by published reports of investigator-initiated open label clinical studies. Because chronic lithium, carbamazepine and valproate decrease the turnover of arachidonic acid (AA) but not docosahexaenoic acid (DHA) in brain phospholipids of the awake rat, we tested if topiramate would produce similar results. Rats received either topiramate (20 mg/kg twice per day) or vehicle for 14 days and then while unanesthetized were infused intravenously with either [1-14C] AA or [1-14C] DHA for 5 min while blood was collected from the femoral artery at fixed times. Topiramate did not alter the incorporation rate of AA or DHA from their respective brain acyl-CoA pool into brain phospholipids, nor the turnover of AA and DHA in brain phospholipids. The results of our study indicate that topiramate does not possess a pharmacological property that three drugs with proven efficacy in treating bipolar disorder have in common.

Keywords

Arachidonic acid brain bipolar disorder mood stabilizer anti-epileptic topiramate lithium mania turnover metabolism kinetics

Abbreviations

AA

arachidonic acid

DHA

docosahexaenoic acid

PC

choline glycerophospholipid

PS

phosphatidylserine

PI

phosphatidylinositoI

PE

ethanolamine glycerophospholipid

FAME

fatty acid methyl ester

sn

stereospecifically numbered

Copyright information

© Springer Science+Business Media, Inc. 2005